Lrp1 is a host entry factor for Rift Valley fever virus.
Animals
Antibody Specificity
/ immunology
Base Sequence
Brain
/ pathology
CRISPR-Cas Systems
/ genetics
Cell Membrane
/ metabolism
Cells, Cultured
Glycoproteins
/ metabolism
Glycosaminoglycans
/ metabolism
Glycosylation
Host-Pathogen Interactions
Humans
LDL-Receptor Related Protein-Associated Protein
/ metabolism
Ligands
Low Density Lipoprotein Receptor-Related Protein-1
/ deficiency
Membrane Glycoproteins
/ metabolism
Mice
Protein Binding
Protein Denaturation
Rift Valley Fever
/ pathology
Rift Valley fever virus
/ immunology
Virus Internalization
CRISPR screen
Lrp1
Rift Valley fever virus
viral entry
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
received:
21
11
2020
revised:
29
04
2021
accepted:
01
09
2021
pubmed:
25
9
2021
medline:
8
1
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
Rift Valley fever virus (RVFV) is a zoonotic pathogen with pandemic potential. RVFV entry is mediated by the viral glycoprotein (Gn), but host entry factors remain poorly defined. Our genome-wide CRISPR screen identified low-density lipoprotein receptor-related protein 1 (mouse Lrp1/human LRP1), heat shock protein (Grp94), and receptor-associated protein (RAP) as critical host factors for RVFV infection. RVFV Gn directly binds to specific Lrp1 clusters and is glycosylation independent. Exogenous addition of murine RAP domain 3 (mRAP
Identifiants
pubmed: 34559985
pii: S0092-8674(21)01048-5
doi: 10.1016/j.cell.2021.09.001
pmc: PMC8786218
mid: NIHMS1742896
pii:
doi:
Substances chimiques
Glycoproteins
0
Glycosaminoglycans
0
LDL-Receptor Related Protein-Associated Protein
0
Ligands
0
Low Density Lipoprotein Receptor-Related Protein-1
0
Membrane Glycoproteins
0
endoplasmin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5163-5178.e24Subventions
Organisme : NIAID NIH HHS
ID : T32 AI060525
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI106688
Pays : United States
Organisme : NIGMS NIH HHS
ID : P41 GM103422
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS101100
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI059371
Pays : United States
Organisme : NIAID NIH HHS
ID : K08 AI144033
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI123926
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI120943
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM136766
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI130152
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI161765
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI107056
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150792
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI163603
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142784
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143292
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests H.W.V. is a founder of Casma Therapeutics and pierianDx and is employed by Vir Biotechnology. None of these companies funded the work reported here. Invention disclosures for method of use for Lrp1 interaction with RVFV Gn (G.K.A., A.L.H., D.W.L., H.W.V., and S.S.G.) and for the use of anti-Lrp1 antibodies by U Toronto (S.S.S., S.M., and G.K.A.) have been filed. Inclusion and diversity We worked to ensure sex balance in the selection of non-human subjects. We worked to ensure diversity in experimental samples through the selection of the cell lines. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list.
Références
J Virol. 2013 Apr;87(8):4384-94
pubmed: 23388721
J Am Mosq Control Assoc. 2008 Dec;24(4):502-7
pubmed: 19181056
Nat Biotechnol. 2016 Feb;34(2):184-191
pubmed: 26780180
Front Cardiovasc Med. 2019 Apr 26;6:51
pubmed: 31080804
Nat Commun. 2017 Jun 08;8:15576
pubmed: 28593988
Traffic. 2016 Jun;17(6):639-56
pubmed: 26990254
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):58-64
pubmed: 20682907
PLoS One. 2015 Jan 21;10(1):e0116722
pubmed: 25607955
Viruses. 2016 May 23;8(5):
pubmed: 27223297
Biochemistry. 2003 Dec 23;42(50):14913-20
pubmed: 14674767
Vet Pathol. 2020 Jan;57(1):66-81
pubmed: 31842723
PLoS Negl Trop Dis. 2011 Sep;5(9):e1229
pubmed: 21980543
Biotechniques. 1993 Sep;15(3):532-4, 536-7
pubmed: 7692896
Eur J Immunol. 1987 Oct;17(10):1491-8
pubmed: 3119352
J Virol. 2012 Dec;86(24):13767-71
pubmed: 23015725
J Mol Biol. 2013 Feb 22;425(4):803-11
pubmed: 23219464
Nature. 2018 May;557(7706):570-574
pubmed: 29769725
Int Rev Cytol. 2001;209:79-116
pubmed: 11580203
J Biol Chem. 1999 Oct 29;274(44):31305-11
pubmed: 10531329
J Med Entomol. 2013 Sep;50(5):1111-7
pubmed: 24180117
Med Vet Entomol. 2017 Dec;31(4):365-372
pubmed: 28782121
J Virol. 2012 Apr;86(8):4204-12
pubmed: 22345465
Am J Pathol. 2014 Jan;184(1):18-27
pubmed: 24128688
Nat Microbiol. 2019 May;4(5):854-863
pubmed: 30833735
Front Microbiol. 2020 Aug 21;11:1962
pubmed: 32973712
Sci Adv. 2018 Dec 05;4(12):eaau9812
pubmed: 30525107
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16497-16506
pubmed: 31346084
PLoS Pathog. 2019 Jun 20;15(6):e1007833
pubmed: 31220182
Clin Infect Dis. 2003 Oct 15;37(8):1084-92
pubmed: 14523773
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7564-E7573
pubmed: 28827346
Trends Cell Biol. 1998 Jul;8(7):272-6
pubmed: 9714598
PLoS Negl Trop Dis. 2011 Dec;5(12):e1421
pubmed: 22163058
J Biol Chem. 2017 Jan 20;292(3):912-924
pubmed: 27956551
Cell Host Microbe. 2011 Jul 21;10(1):75-88
pubmed: 21767814
Cell Signal. 2020 Nov;75:109761
pubmed: 32861744
J Virol. 2014 Feb;88(4):2235-45
pubmed: 24335307
J Clin Invest. 2001 Sep;108(6):779-84
pubmed: 11560943
PLoS One. 2013 May 13;8(5):e64145
pubmed: 23675525
Am J Trop Med Hyg. 2010 Aug;83(2 Suppl):52-7
pubmed: 20682906
J Biol Chem. 2016 Jan 1;291(1):447-61
pubmed: 26546677
J Neuroinflammation. 2012 May 31;9:115
pubmed: 22651808
Cell. 1992 Oct 30;71(3):411-21
pubmed: 1423604
Front Microbiol. 2012 Jul 19;3:254
pubmed: 22837754
Front Microbiol. 2015 Jun 30;6:664
pubmed: 26175725
J Biol Chem. 2015 Jul 10;290(28):17262-8
pubmed: 26013822
PLoS Pathog. 2017 May 1;13(5):e1006370
pubmed: 28459842
Cell Rep. 2015 Dec 15;13(10):2064-71
pubmed: 26628375
Nature. 2020 Apr;580(7803):381-385
pubmed: 32296178
J Virol. 2008 Nov;82(21):10341-8
pubmed: 18715915
J Biol Chem. 2003 May 16;278(20):17986-92
pubmed: 12637503
J Virol. 2015 Nov 18;90(3):1414-23
pubmed: 26581979
Nat Commun. 2018 Jan 31;9(1):465
pubmed: 29386621